NanoViricides sets ATM capacity to $0 under S-3 I.B.6
NanoViricides, Inc. filed Amendment No. 2 to its prospectus supplement for its at-the-market offering, updating the maximum amount available to sell to $0 under its Form S-3 program with D. Boral Capital LLC (formerly EF Hutton) as agent.
Rhea-AI Filing Summary
NanoViricides, Inc. filed Amendment No. 2 to its prospectus supplement for its at-the-market offering, updating the maximum amount available to sell to $0 under its Form S-3 program with D. Boral Capital LLC (formerly EF Hutton) as agent.
The company states it may not currently offer and sell common stock through or to the agent pursuant to the prospectus as amended. This update reflects the Form S-3 General Instruction I.B.6 limitations tied to public float. As of November 10, 2025, public float was $34,719,086, based on 17,359,543 non‑affiliate shares at $2.00 per share. Over the prior 12 months, the company has offered and sold approximately $5,009,140 of common stock under I.B.6.
The company notes that if its public float changes, it may sell up to one‑third of its public float on Form S‑3, subject to the Sales Agreement, and that the I.B.6 cap no longer applies if public float exceeds $75 million.
Positive
- None.
Negative
- None.
Insights
ATM capacity reduced to $0 under I.B.6 float limits.
NanoViricides has amended its ATM prospectus to set the current sellable amount to $0. The filing ties this to Form S-3 General Instruction I.B.6, which caps primary offerings to one‑third of public float when float is below $75 million.
As of November 10, 2025, the company’s public float was $34,719,086, and it has sold about $5,009,140 over the prior 12 months under I.B.6. This amendment states they may not currently offer and sell via the agent under the amended prospectus.
Future activity depends on public float levels and the Sales Agreement terms. If public float rises above $75 million, the I.B.6 cap falls away; otherwise, sales remain constrained by the one‑third limit.
FAQ
What changed in NanoViricides (NNVC) ATM program?
What is NNVC’s public float used for I.B.6?
How much has NNVC sold under I.B.6 in the last 12 months?
When could NNVC resume ATM sales?
Who is the sales agent for NNVC’s ATM?
Is NNVC’s stock exchange listing affected?
AI-generated analysis. How Rhea-AI works. Not financial advice.
| AMENDMENT NO. 2 DATED NOVEMBER 12, 2025 To Prospectus Supplement dated April 5, 2024 (To Prospectus Dated May 22, 2023 and Prospectus Supplement dated August 7, 2023) |
Filed pursuant to Rule 424(b)(5) Registration No. 333-271706 |
NANOVIRICIDES, INC.
Up to $0 of
Common Stock
This Amendment No. 2 to Prospectus Supplement (this “Amendment”) amends and supplements the information in our prospectus, dated May 22, 2023 (the “Prospectus”), and the prospectus supplements, dated August 7, 2023 and April 5, 2024 (the “Prospectus Supplements”), each of which were filed pursuant to our registration statement on Form S-3 (File No. 333-271706) (the “Registration Statement”). This Amendment should be read in conjunction with the Prospectus and Prospectus Supplements, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prospectus and the Prospectus Supplements. This Amendment is not complete without, and may only be delivered or utilized in connection with, the Prospectus and Prospectus Supplements, and any future amendments or supplements thereto.
This Amendment is being filed in connection with our previously announced “at the market offering” program, and to update the maximum amount of shares of our common stock, par value $0.00001 per share, that we may issue and sell from time to time through or to EF Hutton LLC (the “Agent”, now known as D. Boral Capital LLC) as sales agent or principal, pursuant to the terms of our previously announced At Market Issuance Sales Agreement, dated April 5, 2024, between us and the Agent (the “Sales Agreement”).
Our common stock is listed on the New York Stock Exchange, or NYSE, under the symbol “NNVC”. As of November 10, 2025, the aggregate market value of our common stock held by non-affiliates, or the public float, pursuant to General Instruction I.B.6 of Form S-3 was $34,719,086, which was calculated based on 17,359,543 shares of our common stock outstanding held by non-affiliates as of November 10, 2025 and at a price of $2.00 per share, the last reported sale price for our common stock on November 3, 2025. As of the date hereof, we have offered and sold approximately $5,009,140 of shares of our common stock pursuant to General Instruction I.B.6 of Form S-3 during the prior 12 calendar month period that ends on and includes the date hereof. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in public primary offerings on Form S-3 with a value exceeding one-third of our public float (as defined by General Instruction I.B.6) in any 12-calendar month period so long as our public float remains below $75 million.
We are filing this Amendment to amend the Prospectus Supplements to decrease the maximum amount we are eligible to sell under our Registration Statement pursuant to General Instruction I.B.6 of Form S-3. Accordingly, in accordance with the terms of the Sales Agreement, we may not currently offer and sell common stock through or to the Agent pursuant to the Prospectus and Prospectus Supplements, as amended by this Amendment. However, in the event that our public float increases or decreases, we may sell securities in public primary offerings on Form S-3 with a value of up to one-third of our public float, as calculated pursuant to General Instruction I.B.6 and subject to the terms of the Sales Agreement. In the event that our public float increases above $75 million, we will no longer be subject to the limits in General Instruction I.B.6 of Form S-3.
Investing in our common stock involves risks. You should carefully consider the risks described under “Risk Factors” in the Prospectus and Prospectus Supplements, as well as those described in our other reports and documents we filed with the Securities and Exchange Commission (the “SEC”) that we incorporate by reference in the Prospectus, the Prospectus Supplements and this Amendment, before making a decision to invest in our common stock.
Neither the SEC, any state securities commission, nor any other regulatory body has approved or disapproved of these securities or determined if this Amendment is accurate or complete. Any representation to the contrary is a criminal offense.
The date of this Amendment No. 2 to Prospectus Supplement is November 12, 2025.